Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Dotan, Efrat, Cohen, Steven J., Starodub, Alexander N., Lieu, Christopher H., Messersmith, Wells A., Simpson, Pamela S., Guarino, Michael J., Marshall, John L., Goldberg, Richard M., Hecht, J. Randolph, Wegener, William A., Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Berlin, Jordan D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2017
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259133/
https://ncbi.nlm.nih.gov/pubmed/28817371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.9011
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi